Postoperative Calcitonin Monitoring in Medullary Thyroid Carcinoma

Primary Reasons for Measurement

The National Comprehensive Cancer Network recommends measuring calcitonin levels after Medullary Thyroid Carcinoma (MTC) resection because they serve as the cornerstone of postoperative assessment for residual disease, directly guide further management decisions, and predict long-term survival outcomes 1, 2
Approximately 80% of patients with palpable MTC and 50% of those with nonpalpable but macroscopic MTC who undergo supposedly curative resection have serum calcitonin values indicative of residual disease 1, 3
Calcitonin is produced exclusively in parafollicular cells, making it highly specific for detecting persistent or recurrent MTC 2, 4

High postoperative serum calcitonin values are associated with significantly higher mortality rates, with more than 50% of patients experiencing recurrence during a mean follow-up of 10 years 3, 6
The prognosis for patients with postoperative hypercalcitoninemia depends primarily on the extent of disease at initial surgery 3, 7

Basal serum concentrations of calcitonin and CEA should be measured 2 or 3 months postoperatively to determine the need for additional evaluation 1, 3, 4
Patients with basal serum calcitonin <150 pg/mL: Neck ultrasound is sufficient, as these levels are usually associated with locoregional disease and very rarely with distant metastases 8
Patients with basal calcitonin ≥150 pg/mL: Mandatory comprehensive imaging including contrast-enhanced CT or MRI of neck, chest, and abdomen with liver protocol 5, 8

Patients with undetectable calcitonin levels can be followed up with annual measurements of serum markers, while those with detectable levels require more intensive surveillance every 6-12 months 2, 5, 7
Undetectable calcitonin indicates only a 3% chance of recurrence during long-term follow-up 8

Patients with undetectable calcitonin levels: Annual measurements of serum markers and no additional imaging required if calcitonin and CEA remain stable 2, 5, 9
Patients with detectable but <150 pg/mL calcitonin: Neck ultrasound recommended and additional imaging may be deferred until serum calcitonin rises over time 2, 8
Patients with calcitonin ≥150 pg/mL: Contrast-enhanced CT or MRI of neck, chest, and abdomen with liver protocol and bone scan, FDG-PET scan, or MRI of axial skeleton should be considered 2, 5, 8

Outside of clinical trials, no therapeutic intervention based on abnormal markers alone is recommended without imaging confirmation of disease 2, 10